HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zero Count Adds Up To 70,000-Bottle Ranitidine Recall For AuroMedics

Executive Summary

Additional recent recalls include 19,000 bottles of product marketed by Fitoterapia USA and labeled as liquid vitamin C but found to contain erectile dysfunction drug taldalafil .Ongoing testing of ranitidine drugs by FDA and manufacturers led to Aurobindo Pharma USA recall of one lot of OTC 150-mg tablets.

You may also be interested in...

Expanding US FDA Mandatory Recall Authority To All Drugs Gets House Appropriators’ Approval

Appropriators’ FDA FY 2021 budget includes amendment to expand its mandatory recall authority introduced by chairman of subcommittee with oversight of agency’s budget, Rep. Sanford Bishop. He said the agency should be able to force drug product recalls as it already can for vaccines, medical devices and products containing ingredients also scheduled as controlled substances.

FDA Finds Ranitidine Poses Little Risk, But Concerns Linger

Ranitidine no more carcinogenic than grilled meat, says FDA drug center director Janet Woodcock. Agency finds NDMA levels in ranitidine drugs well below those claimed by Valisure, online pharmacy asking FDA to order drug off US market.

EMA Tells Firms To Evaluate OTCs For Carcinogenic Nitrosamines

Firms operating in the EU given six months to evaluate all OTC drugs containing chemically synthesized APIs for presence of nitrosamines, a probable human carcinogen. The order from EMA comes with a review of ranitidine underway after nitrosamine NDMA was detected in a number of OTC and Rx drugs.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts